Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19171985 | 0.90 | FKBP1A (0.47) | FKBP1AKDM4EALDH1A1TSHRMAPK1 | |
| SCHEMBL12881542 | 0.89 | FKBP1A (0.48) | FKBP1AKDM4EALDH1A1TSHRMAPK1 | |
| SCHEMBL5176485 | 0.88 | FKBP1A (0.47) | FKBP1AKDM4EALDH1A1TSHRMAPK1 | |
| SCHEMBL20310851 | 0.84 | FKBP1A (0.43) | FKBP1AKDM4EALDH1A1TSHRMAPK1 | |
| SCHEMBL1207252 | 0.83 | FKBP1A (0.42) | FKBP1AKDM4EALDH1A1TSHRMAPK1 | |
| SCHEMBL12881530 | 0.83 | SMN1; SMN2 (0.42) | FKBP1AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL24846753 | 0.78 | FKBP1A (0.55) | FKBP1AKDM4EALDH1A1TSHRMAPK1 | |
| SCHEMBL652160 | 0.78 | FKBP1A (0.55) | FKBP1AKDM4EALDH1A1TSHRMAPK1 | |
| SCHEMBL3558877 | 0.78 | FKBP1A (0.46) | FKBP1AKDM4EALDH1A1TSHRMAPK1 | |
| SCHEMBL6541395 | 0.77 | FKBP1A (0.62) | FKBP1AKDM4EALDH1A1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009029375-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062268-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062268-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP11, PARP2 | FKBP1A 2967/4885KDM4E 1849/4885ALDH1A1 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.